SCHEMBL8964776

SCHEMBL8964776

Cc1ccsc1CN1CCCN(c2cccc(C(=O)c3cncc(Br)c3)n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 5/20 0.46
HTT P42858 4/20 0.40
HPGD P15428 2/20 0.40
MAPT P10636 2/20 0.40
USP2 O75604 1/20 0.40
HSD17B14 Q9BPX1 2/20 0.39
PRKCQ Q04759 1/20 0.38
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.34
DRD3 P35462 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
ALOX15 P16050 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CASP1 P29466 1/20 0.34
CASP4 P49662 1/20 0.34
CASP5 P51878 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8964435 0.87 KDM4E (0.51) ALDH1A1KDM4EHSD17B14PRKCQLMNA
SCHEMBL8964520 0.85 HTT (0.49) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL8970118 0.85 PRKCQ (0.49) ALDH1A1KDM4EPRKCQLMNA
SCHEMBL8964294 0.83 CASP1 (0.48) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL8964552 0.82 HSD17B14 (0.42) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL8964288 0.81 PIM1 (0.45) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL8963966 0.81 HSD17B14 (0.55) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL8964080 0.80 CACNA1I (0.48) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL8964454 0.80 HSD17B14 (0.42) ALDH1A1KDM4EHTTHPGDMAPT
SCHEMBL8964479 0.78 CASP1 (0.47) ALDH1A1HTTHPGDMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221334-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 US disclosed
US-8741931-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2014-06-03 US disclosed
US-20120214799-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-23 US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221334-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 ALDH1A1 4211/4885KDM4E 990/4885HTT 983/4885
US-20120214799-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 ALDH1A1 4211/4885KDM4E 990/4885HTT 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.